世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
四肢軟部肉腫の世界市場成長 2024-2030Global Extremities Soft Tissue Sarcomas Market Growth 2024-2030 軟部肉腫は、小児から成人まで罹患する可能性があり、身体の軟部組織で増殖する悪性腫瘍の一群である。比較的まれな悪性腫瘍で、毎年10万人あたり2～3人しか罹患しない。軟部肉腫は筋肉、皮膚の深層、脂肪、血管... もっと見る
日本語のページは自動翻訳を利用し作成しています。 
サマリー軟部肉腫は、小児から成人まで罹患する可能性があり、身体の軟部組織で増殖する悪性腫瘍の一群である。比較的まれな悪性腫瘍で、毎年10万人あたり2～3人しか罹患しない。軟部肉腫は筋肉、皮膚の深層、脂肪、血管、神経、その他の結合組織で増殖する。軟部肉腫は体のどこにでも発生する可能性があるが、多くは腕や脚に発生する。世界の四肢軟部肉腫市場規模は、2024年の100万米ドルから2030年には100万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は%であると予測されている。 LPインフォメーション社の最新調査レポート「四肢軟部肉腫の産業予測」は、過去の販売実績と2023年の四肢軟部肉腫の世界総販売実績を調査し、2024年から2030年までの四肢軟部肉腫の販売予測について地域別・市場分野別に包括的に分析しています。本レポートでは、四肢軟部肉腫の売上高を地域別、市場分野別、サブセクター別に分類し、世界の四肢軟部肉腫産業の詳細な分析を百万米ドル単位で提供しています。 このインサイトレポートでは、世界の四肢軟部肉腫の状況を包括的に分析し、製品区分、企業形成、収益、市場シェア、最新動向、M&A活動に関する主要動向を明らかにします。また、本レポートでは、加速する世界の四肢軟部肉腫市場におけるこれらの企業の独自のポジションをより良く理解するために、四肢軟部肉腫のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当てて、主要グローバル企業の戦略を分析しています。 当インサイトレポートでは、四肢軟部肉腫の世界的な見通しを形成している主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に分類して予測を行い、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、この調査予測は世界の四肢軟部肉腫の現状と将来の軌道について非常にニュアンスのある見解を提供します。 四肢軟部肉腫の米国市場は、2023年の100万米ドルから2030年までに100万米ドルに増加し、2024年から2030年までの年平均成長率は％と推定される。 四肢軟部肉腫の中国市場は、2023年の百万米ドルから2030年には百万米ドルに、2024年から2030年までの年平均成長率は％と推定される。 四肢軟部肉腫のヨーロッパ市場は、2023年の百万米ドルから2030年には百万米ドルに増加し、2024年から2030年までの年平均成長率は％と推定される。 四肢軟部肉腫の世界的な主要企業は、Novartis、Pfizer、Bristol-Myers Squibb、Merck、GSKなどである。売上高では、世界の2大企業が2023年にほぼ％のシェアを占めている。 のシェアを占めている。 本レポートでは、四肢軟部肉腫市場の製品タイプ、用途、主要メーカー、主要地域および国別の包括的な概要、市場シェア、成長機会を紹介する。 タイプ別セグメント 化学療法薬 標的治療薬 免疫療法薬 ホルモン療法薬 用途別セグメント 病院 クリニック その他 本レポートはまた、市場を地域別に分けています： 南北アメリカ アメリカ カナダ メキシコ ブラジル APAC 中国 日本 韓国 東南アジア インド オーストラリア ヨーロッパ ドイツ フランス 英国 イタリア ロシア 中東・アフリカ エジプト 南アフリカ イスラエル トルコ GCC諸国 以下の企業は、一次専門家から収集したインプットと、企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。 ノバルティス ファイザー ブリストル・マイヤーズ スクイブ メルク GSK バイエル アドベンシェン・ラボラトリーズ ブループリント医薬品 バイオホライゾン バイオメット ガイストリッヒ スミス・アンド・ネフュー RTIバイオロジクス ミメデックス ライフセル アトリウムメディカル ジマー・ホールディングス クックメディカル デンツプライ メドトロニック ストライカー エチコン ボストン・サイエンティフィック アメリカン・メディカル・システムズ インテグラライフサイエンスとシタジェニックス 本レポートで扱う主な質問 世界の四肢軟部肉腫市場の10年展望は？ 世界および地域別で、四肢軟部肉腫市場の成長を促進する要因は何か？ 市場別、地域別に最も急成長する技術は何か？ 末端市場規模別に、四肢軟部肉腫の市場機会はどのように異なるのか？ 四肢軟部肉腫のタイプ別、用途別の内訳は？ 目次1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Extremities Soft Tissue Sarcomas Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Extremities Soft Tissue Sarcomas by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Extremities Soft Tissue Sarcomas by Country/Region, 2019, 2023 & 2030 2.2 Extremities Soft Tissue Sarcomas Segment by Type 2.2.1 Chemotherapy Drugs 2.2.2 Targeted therapy Drugs 2.2.3 Immunotherapy Drugs 2.2.4 Hormonal therapy Drugs 2.3 Extremities Soft Tissue Sarcomas Sales by Type 2.3.1 Global Extremities Soft Tissue Sarcomas Sales Market Share by Type (2019-2024) 2.3.2 Global Extremities Soft Tissue Sarcomas Revenue and Market Share by Type (2019-2024) 2.3.3 Global Extremities Soft Tissue Sarcomas Sale Price by Type (2019-2024) 2.4 Extremities Soft Tissue Sarcomas Segment by Application 2.4.1 Hospital 2.4.2 Clinic 2.4.3 Other 2.5 Extremities Soft Tissue Sarcomas Sales by Application 2.5.1 Global Extremities Soft Tissue Sarcomas Sale Market Share by Application (2019-2024) 2.5.2 Global Extremities Soft Tissue Sarcomas Revenue and Market Share by Application (2019-2024) 2.5.3 Global Extremities Soft Tissue Sarcomas Sale Price by Application (2019-2024) 3 Global by Company 3.1 Global Extremities Soft Tissue Sarcomas Breakdown Data by Company 3.1.1 Global Extremities Soft Tissue Sarcomas Annual Sales by Company (2019-2024) 3.1.2 Global Extremities Soft Tissue Sarcomas Sales Market Share by Company (2019-2024) 3.2 Global Extremities Soft Tissue Sarcomas Annual Revenue by Company (2019-2024) 3.2.1 Global Extremities Soft Tissue Sarcomas Revenue by Company (2019-2024) 3.2.2 Global Extremities Soft Tissue Sarcomas Revenue Market Share by Company (2019-2024) 3.3 Global Extremities Soft Tissue Sarcomas Sale Price by Company 3.4 Key Manufacturers Extremities Soft Tissue Sarcomas Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Extremities Soft Tissue Sarcomas Product Location Distribution 3.4.2 Players Extremities Soft Tissue Sarcomas Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Extremities Soft Tissue Sarcomas by Geographic Region 4.1 World Historic Extremities Soft Tissue Sarcomas Market Size by Geographic Region (2019-2024) 4.1.1 Global Extremities Soft Tissue Sarcomas Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Extremities Soft Tissue Sarcomas Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Extremities Soft Tissue Sarcomas Market Size by Country/Region (2019-2024) 4.2.1 Global Extremities Soft Tissue Sarcomas Annual Sales by Country/Region (2019-2024) 4.2.2 Global Extremities Soft Tissue Sarcomas Annual Revenue by Country/Region (2019-2024) 4.3 Americas Extremities Soft Tissue Sarcomas Sales Growth 4.4 APAC Extremities Soft Tissue Sarcomas Sales Growth 4.5 Europe Extremities Soft Tissue Sarcomas Sales Growth 4.6 Middle East & Africa Extremities Soft Tissue Sarcomas Sales Growth 5 Americas 5.1 Americas Extremities Soft Tissue Sarcomas Sales by Country 5.1.1 Americas Extremities Soft Tissue Sarcomas Sales by Country (2019-2024) 5.1.2 Americas Extremities Soft Tissue Sarcomas Revenue by Country (2019-2024) 5.2 Americas Extremities Soft Tissue Sarcomas Sales by Type (2019-2024) 5.3 Americas Extremities Soft Tissue Sarcomas Sales by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Extremities Soft Tissue Sarcomas Sales by Region 6.1.1 APAC Extremities Soft Tissue Sarcomas Sales by Region (2019-2024) 6.1.2 APAC Extremities Soft Tissue Sarcomas Revenue by Region (2019-2024) 6.2 APAC Extremities Soft Tissue Sarcomas Sales by Type (2019-2024) 6.3 APAC Extremities Soft Tissue Sarcomas Sales by Application (2019-2024) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Extremities Soft Tissue Sarcomas by Country 7.1.1 Europe Extremities Soft Tissue Sarcomas Sales by Country (2019-2024) 7.1.2 Europe Extremities Soft Tissue Sarcomas Revenue by Country (2019-2024) 7.2 Europe Extremities Soft Tissue Sarcomas Sales by Type (2019-2024) 7.3 Europe Extremities Soft Tissue Sarcomas Sales by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Extremities Soft Tissue Sarcomas by Country 8.1.1 Middle East & Africa Extremities Soft Tissue Sarcomas Sales by Country (2019-2024) 8.1.2 Middle East & Africa Extremities Soft Tissue Sarcomas Revenue by Country (2019-2024) 8.2 Middle East & Africa Extremities Soft Tissue Sarcomas Sales by Type (2019-2024) 8.3 Middle East & Africa Extremities Soft Tissue Sarcomas Sales by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Extremities Soft Tissue Sarcomas 10.3 Manufacturing Process Analysis of Extremities Soft Tissue Sarcomas 10.4 Industry Chain Structure of Extremities Soft Tissue Sarcomas 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Extremities Soft Tissue Sarcomas Distributors 11.3 Extremities Soft Tissue Sarcomas Customer 12 World Forecast Review for Extremities Soft Tissue Sarcomas by Geographic Region 12.1 Global Extremities Soft Tissue Sarcomas Market Size Forecast by Region 12.1.1 Global Extremities Soft Tissue Sarcomas Forecast by Region (2025-2030) 12.1.2 Global Extremities Soft Tissue Sarcomas Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country (2025-2030) 12.3 APAC Forecast by Region (2025-2030) 12.4 Europe Forecast by Country (2025-2030) 12.5 Middle East & Africa Forecast by Country (2025-2030) 12.6 Global Extremities Soft Tissue Sarcomas Forecast by Type (2025-2030) 12.7 Global Extremities Soft Tissue Sarcomas Forecast by Application (2025-2030) 13 Key Players Analysis 13.1 Novartis 13.1.1 Novartis Company Information 13.1.2 Novartis Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.1.3 Novartis Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Novartis Main Business Overview 13.1.5 Novartis Latest Developments 13.2 Pfizer 13.2.1 Pfizer Company Information 13.2.2 Pfizer Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.2.3 Pfizer Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 Pfizer Main Business Overview 13.2.5 Pfizer Latest Developments 13.3 Bristol-Myers Squibb 13.3.1 Bristol-Myers Squibb Company Information 13.3.2 Bristol-Myers Squibb Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.3.3 Bristol-Myers Squibb Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Bristol-Myers Squibb Main Business Overview 13.3.5 Bristol-Myers Squibb Latest Developments 13.4 Merck 13.4.1 Merck Company Information 13.4.2 Merck Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.4.3 Merck Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Merck Main Business Overview 13.4.5 Merck Latest Developments 13.5 GSK 13.5.1 GSK Company Information 13.5.2 GSK Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.5.3 GSK Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 GSK Main Business Overview 13.5.5 GSK Latest Developments 13.6 Bayer 13.6.1 Bayer Company Information 13.6.2 Bayer Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.6.3 Bayer Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Bayer Main Business Overview 13.6.5 Bayer Latest Developments 13.7 Advenchen Laboratories 13.7.1 Advenchen Laboratories Company Information 13.7.2 Advenchen Laboratories Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.7.3 Advenchen Laboratories Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Advenchen Laboratories Main Business Overview 13.7.5 Advenchen Laboratories Latest Developments 13.8 Blueprint Medicines 13.8.1 Blueprint Medicines Company Information 13.8.2 Blueprint Medicines Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.8.3 Blueprint Medicines Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Blueprint Medicines Main Business Overview 13.8.5 Blueprint Medicines Latest Developments 13.9 BioHorizons 13.9.1 BioHorizons Company Information 13.9.2 BioHorizons Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.9.3 BioHorizons Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 BioHorizons Main Business Overview 13.9.5 BioHorizons Latest Developments 13.10 Biomet 13.10.1 Biomet Company Information 13.10.2 Biomet Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.10.3 Biomet Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Biomet Main Business Overview 13.10.5 Biomet Latest Developments 13.11 Geistlich 13.11.1 Geistlich Company Information 13.11.2 Geistlich Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.11.3 Geistlich Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Geistlich Main Business Overview 13.11.5 Geistlich Latest Developments 13.12 Smith & Nephew 13.12.1 Smith & Nephew Company Information 13.12.2 Smith & Nephew Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.12.3 Smith & Nephew Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 Smith & Nephew Main Business Overview 13.12.5 Smith & Nephew Latest Developments 13.13 RTI Biologics 13.13.1 RTI Biologics Company Information 13.13.2 RTI Biologics Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.13.3 RTI Biologics Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 RTI Biologics Main Business Overview 13.13.5 RTI Biologics Latest Developments 13.14 MiMedx 13.14.1 MiMedx Company Information 13.14.2 MiMedx Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.14.3 MiMedx Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 MiMedx Main Business Overview 13.14.5 MiMedx Latest Developments 13.15 LifeCell 13.15.1 LifeCell Company Information 13.15.2 LifeCell Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.15.3 LifeCell Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 LifeCell Main Business Overview 13.15.5 LifeCell Latest Developments 13.16 Atrium Medical 13.16.1 Atrium Medical Company Information 13.16.2 Atrium Medical Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.16.3 Atrium Medical Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.16.4 Atrium Medical Main Business Overview 13.16.5 Atrium Medical Latest Developments 13.17 Zimmer Holdings 13.17.1 Zimmer Holdings Company Information 13.17.2 Zimmer Holdings Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.17.3 Zimmer Holdings Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.17.4 Zimmer Holdings Main Business Overview 13.17.5 Zimmer Holdings Latest Developments 13.18 Cook Medical 13.18.1 Cook Medical Company Information 13.18.2 Cook Medical Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.18.3 Cook Medical Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.18.4 Cook Medical Main Business Overview 13.18.5 Cook Medical Latest Developments 13.19 Dentsply 13.19.1 Dentsply Company Information 13.19.2 Dentsply Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.19.3 Dentsply Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.19.4 Dentsply Main Business Overview 13.19.5 Dentsply Latest Developments 13.20 Medtronic 13.20.1 Medtronic Company Information 13.20.2 Medtronic Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.20.3 Medtronic Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.20.4 Medtronic Main Business Overview 13.20.5 Medtronic Latest Developments 13.21 Stryker 13.21.1 Stryker Company Information 13.21.2 Stryker Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.21.3 Stryker Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.21.4 Stryker Main Business Overview 13.21.5 Stryker Latest Developments 13.22 Ethicon 13.22.1 Ethicon Company Information 13.22.2 Ethicon Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.22.3 Ethicon Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.22.4 Ethicon Main Business Overview 13.22.5 Ethicon Latest Developments 13.23 Boston Scientific 13.23.1 Boston Scientific Company Information 13.23.2 Boston Scientific Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.23.3 Boston Scientific Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.23.4 Boston Scientific Main Business Overview 13.23.5 Boston Scientific Latest Developments 13.24 American Medical Systems 13.24.1 American Medical Systems Company Information 13.24.2 American Medical Systems Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.24.3 American Medical Systems Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.24.4 American Medical Systems Main Business Overview 13.24.5 American Medical Systems Latest Developments 13.25 Integra LifeSciences and Citagenix 13.25.1 Integra LifeSciences and Citagenix Company Information 13.25.2 Integra LifeSciences and Citagenix Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.25.3 Integra LifeSciences and Citagenix Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.25.4 Integra LifeSciences and Citagenix Main Business Overview 13.25.5 Integra LifeSciences and Citagenix Latest Developments 14 Research Findings and Conclusion
SummarySoft tissue sarcomas are a group of malignant tumors that can affect children and adults and grow in the soft tissues of the body. It is a relatively rare malignancy, affecting only 2-3 people per 100,000 people each year. Soft tissue sarcomas can grow in muscle, deep layers of skin, fat, blood vessels, nerves, and other connective tissues. Although they can appear anywhere in the body, most begin in the arms and legs. Table of Contents1 Scope of the Report1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Extremities Soft Tissue Sarcomas Annual Sales 2019-2030 2.1.2 World Current & Future Analysis for Extremities Soft Tissue Sarcomas by Geographic Region, 2019, 2023 & 2030 2.1.3 World Current & Future Analysis for Extremities Soft Tissue Sarcomas by Country/Region, 2019, 2023 & 2030 2.2 Extremities Soft Tissue Sarcomas Segment by Type 2.2.1 Chemotherapy Drugs 2.2.2 Targeted therapy Drugs 2.2.3 Immunotherapy Drugs 2.2.4 Hormonal therapy Drugs 2.3 Extremities Soft Tissue Sarcomas Sales by Type 2.3.1 Global Extremities Soft Tissue Sarcomas Sales Market Share by Type (2019-2024) 2.3.2 Global Extremities Soft Tissue Sarcomas Revenue and Market Share by Type (2019-2024) 2.3.3 Global Extremities Soft Tissue Sarcomas Sale Price by Type (2019-2024) 2.4 Extremities Soft Tissue Sarcomas Segment by Application 2.4.1 Hospital 2.4.2 Clinic 2.4.3 Other 2.5 Extremities Soft Tissue Sarcomas Sales by Application 2.5.1 Global Extremities Soft Tissue Sarcomas Sale Market Share by Application (2019-2024) 2.5.2 Global Extremities Soft Tissue Sarcomas Revenue and Market Share by Application (2019-2024) 2.5.3 Global Extremities Soft Tissue Sarcomas Sale Price by Application (2019-2024) 3 Global by Company 3.1 Global Extremities Soft Tissue Sarcomas Breakdown Data by Company 3.1.1 Global Extremities Soft Tissue Sarcomas Annual Sales by Company (2019-2024) 3.1.2 Global Extremities Soft Tissue Sarcomas Sales Market Share by Company (2019-2024) 3.2 Global Extremities Soft Tissue Sarcomas Annual Revenue by Company (2019-2024) 3.2.1 Global Extremities Soft Tissue Sarcomas Revenue by Company (2019-2024) 3.2.2 Global Extremities Soft Tissue Sarcomas Revenue Market Share by Company (2019-2024) 3.3 Global Extremities Soft Tissue Sarcomas Sale Price by Company 3.4 Key Manufacturers Extremities Soft Tissue Sarcomas Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Extremities Soft Tissue Sarcomas Product Location Distribution 3.4.2 Players Extremities Soft Tissue Sarcomas Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024) 3.6 New Products and Potential Entrants 3.7 Market M&A Activity & Strategy 4 World Historic Review for Extremities Soft Tissue Sarcomas by Geographic Region 4.1 World Historic Extremities Soft Tissue Sarcomas Market Size by Geographic Region (2019-2024) 4.1.1 Global Extremities Soft Tissue Sarcomas Annual Sales by Geographic Region (2019-2024) 4.1.2 Global Extremities Soft Tissue Sarcomas Annual Revenue by Geographic Region (2019-2024) 4.2 World Historic Extremities Soft Tissue Sarcomas Market Size by Country/Region (2019-2024) 4.2.1 Global Extremities Soft Tissue Sarcomas Annual Sales by Country/Region (2019-2024) 4.2.2 Global Extremities Soft Tissue Sarcomas Annual Revenue by Country/Region (2019-2024) 4.3 Americas Extremities Soft Tissue Sarcomas Sales Growth 4.4 APAC Extremities Soft Tissue Sarcomas Sales Growth 4.5 Europe Extremities Soft Tissue Sarcomas Sales Growth 4.6 Middle East & Africa Extremities Soft Tissue Sarcomas Sales Growth 5 Americas 5.1 Americas Extremities Soft Tissue Sarcomas Sales by Country 5.1.1 Americas Extremities Soft Tissue Sarcomas Sales by Country (2019-2024) 5.1.2 Americas Extremities Soft Tissue Sarcomas Revenue by Country (2019-2024) 5.2 Americas Extremities Soft Tissue Sarcomas Sales by Type (2019-2024) 5.3 Americas Extremities Soft Tissue Sarcomas Sales by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Extremities Soft Tissue Sarcomas Sales by Region 6.1.1 APAC Extremities Soft Tissue Sarcomas Sales by Region (2019-2024) 6.1.2 APAC Extremities Soft Tissue Sarcomas Revenue by Region (2019-2024) 6.2 APAC Extremities Soft Tissue Sarcomas Sales by Type (2019-2024) 6.3 APAC Extremities Soft Tissue Sarcomas Sales by Application (2019-2024) 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Extremities Soft Tissue Sarcomas by Country 7.1.1 Europe Extremities Soft Tissue Sarcomas Sales by Country (2019-2024) 7.1.2 Europe Extremities Soft Tissue Sarcomas Revenue by Country (2019-2024) 7.2 Europe Extremities Soft Tissue Sarcomas Sales by Type (2019-2024) 7.3 Europe Extremities Soft Tissue Sarcomas Sales by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Extremities Soft Tissue Sarcomas by Country 8.1.1 Middle East & Africa Extremities Soft Tissue Sarcomas Sales by Country (2019-2024) 8.1.2 Middle East & Africa Extremities Soft Tissue Sarcomas Revenue by Country (2019-2024) 8.2 Middle East & Africa Extremities Soft Tissue Sarcomas Sales by Type (2019-2024) 8.3 Middle East & Africa Extremities Soft Tissue Sarcomas Sales by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Extremities Soft Tissue Sarcomas 10.3 Manufacturing Process Analysis of Extremities Soft Tissue Sarcomas 10.4 Industry Chain Structure of Extremities Soft Tissue Sarcomas 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Extremities Soft Tissue Sarcomas Distributors 11.3 Extremities Soft Tissue Sarcomas Customer 12 World Forecast Review for Extremities Soft Tissue Sarcomas by Geographic Region 12.1 Global Extremities Soft Tissue Sarcomas Market Size Forecast by Region 12.1.1 Global Extremities Soft Tissue Sarcomas Forecast by Region (2025-2030) 12.1.2 Global Extremities Soft Tissue Sarcomas Annual Revenue Forecast by Region (2025-2030) 12.2 Americas Forecast by Country (2025-2030) 12.3 APAC Forecast by Region (2025-2030) 12.4 Europe Forecast by Country (2025-2030) 12.5 Middle East & Africa Forecast by Country (2025-2030) 12.6 Global Extremities Soft Tissue Sarcomas Forecast by Type (2025-2030) 12.7 Global Extremities Soft Tissue Sarcomas Forecast by Application (2025-2030) 13 Key Players Analysis 13.1 Novartis 13.1.1 Novartis Company Information 13.1.2 Novartis Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.1.3 Novartis Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.1.4 Novartis Main Business Overview 13.1.5 Novartis Latest Developments 13.2 Pfizer 13.2.1 Pfizer Company Information 13.2.2 Pfizer Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.2.3 Pfizer Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.2.4 Pfizer Main Business Overview 13.2.5 Pfizer Latest Developments 13.3 Bristol-Myers Squibb 13.3.1 Bristol-Myers Squibb Company Information 13.3.2 Bristol-Myers Squibb Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.3.3 Bristol-Myers Squibb Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.3.4 Bristol-Myers Squibb Main Business Overview 13.3.5 Bristol-Myers Squibb Latest Developments 13.4 Merck 13.4.1 Merck Company Information 13.4.2 Merck Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.4.3 Merck Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.4.4 Merck Main Business Overview 13.4.5 Merck Latest Developments 13.5 GSK 13.5.1 GSK Company Information 13.5.2 GSK Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.5.3 GSK Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.5.4 GSK Main Business Overview 13.5.5 GSK Latest Developments 13.6 Bayer 13.6.1 Bayer Company Information 13.6.2 Bayer Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.6.3 Bayer Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.6.4 Bayer Main Business Overview 13.6.5 Bayer Latest Developments 13.7 Advenchen Laboratories 13.7.1 Advenchen Laboratories Company Information 13.7.2 Advenchen Laboratories Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.7.3 Advenchen Laboratories Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.7.4 Advenchen Laboratories Main Business Overview 13.7.5 Advenchen Laboratories Latest Developments 13.8 Blueprint Medicines 13.8.1 Blueprint Medicines Company Information 13.8.2 Blueprint Medicines Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.8.3 Blueprint Medicines Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.8.4 Blueprint Medicines Main Business Overview 13.8.5 Blueprint Medicines Latest Developments 13.9 BioHorizons 13.9.1 BioHorizons Company Information 13.9.2 BioHorizons Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.9.3 BioHorizons Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.9.4 BioHorizons Main Business Overview 13.9.5 BioHorizons Latest Developments 13.10 Biomet 13.10.1 Biomet Company Information 13.10.2 Biomet Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.10.3 Biomet Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.10.4 Biomet Main Business Overview 13.10.5 Biomet Latest Developments 13.11 Geistlich 13.11.1 Geistlich Company Information 13.11.2 Geistlich Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.11.3 Geistlich Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.11.4 Geistlich Main Business Overview 13.11.5 Geistlich Latest Developments 13.12 Smith & Nephew 13.12.1 Smith & Nephew Company Information 13.12.2 Smith & Nephew Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.12.3 Smith & Nephew Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.12.4 Smith & Nephew Main Business Overview 13.12.5 Smith & Nephew Latest Developments 13.13 RTI Biologics 13.13.1 RTI Biologics Company Information 13.13.2 RTI Biologics Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.13.3 RTI Biologics Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.13.4 RTI Biologics Main Business Overview 13.13.5 RTI Biologics Latest Developments 13.14 MiMedx 13.14.1 MiMedx Company Information 13.14.2 MiMedx Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.14.3 MiMedx Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.14.4 MiMedx Main Business Overview 13.14.5 MiMedx Latest Developments 13.15 LifeCell 13.15.1 LifeCell Company Information 13.15.2 LifeCell Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.15.3 LifeCell Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.15.4 LifeCell Main Business Overview 13.15.5 LifeCell Latest Developments 13.16 Atrium Medical 13.16.1 Atrium Medical Company Information 13.16.2 Atrium Medical Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.16.3 Atrium Medical Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.16.4 Atrium Medical Main Business Overview 13.16.5 Atrium Medical Latest Developments 13.17 Zimmer Holdings 13.17.1 Zimmer Holdings Company Information 13.17.2 Zimmer Holdings Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.17.3 Zimmer Holdings Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.17.4 Zimmer Holdings Main Business Overview 13.17.5 Zimmer Holdings Latest Developments 13.18 Cook Medical 13.18.1 Cook Medical Company Information 13.18.2 Cook Medical Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.18.3 Cook Medical Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.18.4 Cook Medical Main Business Overview 13.18.5 Cook Medical Latest Developments 13.19 Dentsply 13.19.1 Dentsply Company Information 13.19.2 Dentsply Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.19.3 Dentsply Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.19.4 Dentsply Main Business Overview 13.19.5 Dentsply Latest Developments 13.20 Medtronic 13.20.1 Medtronic Company Information 13.20.2 Medtronic Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.20.3 Medtronic Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.20.4 Medtronic Main Business Overview 13.20.5 Medtronic Latest Developments 13.21 Stryker 13.21.1 Stryker Company Information 13.21.2 Stryker Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.21.3 Stryker Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.21.4 Stryker Main Business Overview 13.21.5 Stryker Latest Developments 13.22 Ethicon 13.22.1 Ethicon Company Information 13.22.2 Ethicon Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.22.3 Ethicon Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.22.4 Ethicon Main Business Overview 13.22.5 Ethicon Latest Developments 13.23 Boston Scientific 13.23.1 Boston Scientific Company Information 13.23.2 Boston Scientific Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.23.3 Boston Scientific Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.23.4 Boston Scientific Main Business Overview 13.23.5 Boston Scientific Latest Developments 13.24 American Medical Systems 13.24.1 American Medical Systems Company Information 13.24.2 American Medical Systems Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.24.3 American Medical Systems Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.24.4 American Medical Systems Main Business Overview 13.24.5 American Medical Systems Latest Developments 13.25 Integra LifeSciences and Citagenix 13.25.1 Integra LifeSciences and Citagenix Company Information 13.25.2 Integra LifeSciences and Citagenix Extremities Soft Tissue Sarcomas Product Portfolios and Specifications 13.25.3 Integra LifeSciences and Citagenix Extremities Soft Tissue Sarcomas Sales, Revenue, Price and Gross Margin (2019-2024) 13.25.4 Integra LifeSciences and Citagenix Main Business Overview 13.25.5 Integra LifeSciences and Citagenix Latest Developments 14 Research Findings and Conclusion
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
LP Information社の医薬品・ヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD（soft）の最新刊レポートよくあるご質問LP Information社はどのような調査会社ですか?LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/20 10:28 158.95 円 165.20 円 201.28 円 |
